AstraZeneca new boss's debut buy
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca's new boss yesterday agreed his first major deal at the pharmaceuticals giant, spending up to $272m (£169m) on the rights to an experimental kidney drug. This month, on his first day in the job, Pascal Soriot suspended Astra's share buybacks for the rest of the year.
Now the drug maker, which is suffering from key medicines running out of patent and a series of failed trials, has bought into a renal treatment, biotech Ardelyx's NHE3 inhibitor programme.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments